We investigated the levels of MMP-7, MMP-26, MMP-3, and MMP-10 in comparison with the levels of a tumor marker (CA125) in the plasma of postmenopausal patients in early stages of endometrial cancer (EC) compared with control groups: patients with benign lesions (myoma uteri) and healthy controls. This evidence concerns the gene MMP26 and neoplasm.